Share your health history and weight loss goals in our secure online questionnaire takes about 5 minutes
The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period
The authors suggest that maintaining extremely large weight losses may be harder biologically
Frontiers inendocrinology, 13, 838410
This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life
These changes to normal gastrointestinal physiology explain why diarrhea (defined as three or more loose or watery stools per day) and other gastrointestinal symptomsincluding nausea, vomiting, constipation, and abdominal painare among the most frequently reported side effects